Raymond Anderson Sells 3,142 Shares of Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Raymond Anderson sold 3,142 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the completion of the sale, the director directly owned 23,751 shares of the company’s stock, valued at approximately $2,654,649.27. This trade represents a 11.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $111.89 on Friday. The firm’s 50-day moving average is $106.44 and its 200-day moving average is $75.00. Monopar Therapeutics Inc. has a 52-week low of $32.77 and a 52-week high of $124.82. The company has a market cap of $750.78 million, a price-to-earnings ratio of -51.56 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.02. Equities analysts predict that Monopar Therapeutics Inc. will post -2.94 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on MNPR. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Barclays reissued an “overweight” rating and set a $128.00 price target (up from $125.00) on shares of Monopar Therapeutics in a research note on Thursday, August 13th. Zacks Research lowered shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Finally, BTIG Research raised their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $118.67.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new position in shares of Monopar Therapeutics during the 3rd quarter worth about $28,000. BNP Paribas Financial Markets raised its position in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter valued at approximately $65,000. JPMorgan Chase & Co. boosted its stake in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Monopar Therapeutics during the second quarter valued at approximately $80,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.